Norway Rare Hemophilia Factors Market Size & Outlook
Related Markets
Norway rare hemophilia factors market highlights
- The Norway rare hemophilia factors market generated a revenue of USD 3.2 million in 2024 and is expected to reach USD 4.3 million by 2030.
- The Norway market is expected to grow at a CAGR of 5.2% from 2025 to 2030.
- In terms of segment, factor vii deficiency was the largest revenue generating factor deficiency in 2024.
- Factor XIII Deficiency is the most lucrative factor deficiency segment registering the fastest growth during the forecast period.
Rare hemophilia factors market data book summary
| Market revenue in 2024 | USD 3.2 million |
| Market revenue in 2030 | USD 4.3 million |
| Growth rate | 5.2% (CAGR from 2025 to 2030) |
| Largest segment | Factor vii deficiency |
| Fastest growing segment | Factor XIII Deficiency |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Factor VII Deficiency, Factor XI Deficiency (Hemophilia C), Factor XIII Deficiency, Other Rare Factor Deficiencies |
| Key market players worldwide | Novo Nordisk A/S ADR, Biogen Inc, Bayer AG, Pfizer Inc, Takeda Pharmaceutical Co Ltd, Baxalta, CSL Ltd, Bio Products Laboratory |
Other key industry trends
- In terms of revenue, Norway accounted for 0.9% of the global rare hemophilia factors market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany rare hemophilia factors market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 19.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Rare Hemophilia Factors Market Scope
Rare Hemophilia Factors Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Baxalta | View profile | 10001+ | Illinois City, Illinois, United States, North America | http://www.baxalta.com |
| Bio Products Laboratory | View profile | 501-1000 | Kingdom City, Missouri, United States, North America | http://www.bplgroup.com/ |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
| Biogen Inc | View profile | 7570 | 225 Binney Street, Cambridge, MA, United States, 02142 | https://www.biogen.com |
| Novo Nordisk A/S ADR | View profile | 66015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | https://www.novonordisk.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
Norway rare hemophilia factors market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare hemophilia factors market will help companies and investors design strategic landscapes.
Factor vii deficiency was the largest segment with a revenue share of 37.5% in 2024. Horizon Databook has segmented the Norway rare hemophilia factors market based on factor vii deficiency, factor xi deficiency (hemophilia c), factor xiii deficiency, other rare factor deficiencies covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Norway rare hemophilia factors market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway rare hemophilia factors market databook
-
Our clientele includes a mix of rare hemophilia factors market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway rare hemophilia factors market , including forecasts for subscribers. This country databook contains high-level insights into Norway rare hemophilia factors market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway rare hemophilia factors market size, by factor deficiency, 2018-2030 (US$M)
Norway Rare Hemophilia Factors Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
